Paediatric glaucoma: Epidemiology and pathogenesis

Article

Dr Brookes explains the importance of identifying the pathogenesis in paediatric glaucoma

Paediatric glaucoma is an important but under-represented subspecialist field of glaucoma. A child diagnosed today with congenital glaucoma has a five times longer life expectancy than a patient diagnosed with primary openangle glaucoma (POAG). Therefore, the impact of a blind child to the family, society as a whole and not least to the child themselves, is immense. It is, therefore, of the utmost importance that the treatments we offer allow these children, to enjoy a sighted and independent life. The importance of this disease is shown by the fact that 18% of children in blind institutions worldwide have glaucoma and it is responsible for 5% of childhood blindness.1

Paediatric glaucoma is an intraocular-dependent disease and the prognosis depends on early, accurate diagnosis, successful control of intraocular pressure (IOP), treatment of associated ocular abnormalities, including refractive error and prevention of amblyopia. There is currently debate as to how the childhood glaucomas should be classified but generally, they can be divided into primary glaucoma, which includes 'primary congenital glaucoma' (PCG), and juvenile-onset glaucoma. Secondary glaucoma, may have a purely ocular phenotype, or be part of a systemic disease, such as a metabolic, chromosomal or connective tissue disorder.

Epidemiology

Of the children diagnosed with PCG, 94% required surgery and 75% had surgery within 4 weeks of diagnosis. The surgery of choice was either goniotomy or trabeculotomy in 87% of cases. In 50% of cases second surgery was required, 31% required 3 surgeries and 15% required 4 operations.

Of the children diagnosed with secondary glaucoma, the most frequent diagnosis was lensrelated (either aphakia or pseudophakia), 23% were secondary to the phacomatoses (most commonly SturgeWeber syndrome), 19% due to uveitis and 10% secondary to anterior segment dysgenesis. As opposed to PCG, most cases (67%) were unilateral and a lower proportion required surgery (64%).

A similar study from Toronto published in 1999 provided similar results, looking at all cases presenting to the Hospital for Sick Children over a 21year period. In this series, 98% of children with PCG required surgery and 50% of aphakic glaucoma cases required surgery, many being managed successfully with medical treatment.3

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.